Lymphatic transport of high-density lipoproteins and chylomicrons

Journal of Clinical Investigation

Volumn 124, Issue 3, 2014, Pages 929-935

  Randolph, Gwendalyn J ^a   Miller, Norman E ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAGDALEN COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHYLOMICRON; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CHOLESTEROL TRANSPORT; CONNECTIVE TISSUE; EXTRAVASCULAR SPACE; HUMAN; HYPERCHOLESTEROLEMIA; INTERSTITIAL FLUID; INTERSTITIUM; LYMPH VESSEL; MACROPHAGE; NONHUMAN; PARTICLE SIZE; PINOCYTOSIS; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; REVIEW; SUBCLAVIAN VEIN; TRANSCYTOSIS;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; CHOLESTEROL; CHYLOMICRONS; EXTRACELLULAR FLUID; HUMANS; LIPOPROTEINS, HDL; LYMPHATIC VESSELS;

EID: 84896751585     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI71610     Document Type: Review

References (76)

1. Glomset JA, Janssen ET, Kennedy R, Dobbins J. Role of plasma lecithin:cholesterol acyltransferase in the metabolism of high density lipoproteins. J Lipid Res. 1966;7(5):638-648.
2. Weinstein DB, Carew TE, Steinberg D. Uptake and degradation of low density lipoprotein by swine arterial smoot muscle cells with inhibition of cholesterol biosynthesis. Biochim Biophys Acta. 1976; 424(3):404-421.
3. Barter PJ, Rye KA. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res. 2012;53(9):1755-1766.
4. Schwartz GG, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089-2099.
5. Boden WE, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-2267.
6. Voight BF, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572-580.
7. Miller NE, et al. Lipoprotein remodeling generates lipid-poor apolipoprotein A-I particles in human interstitial fluid. Am J Physiol Endocrinol Metab. 2013;304(3):E321-E328.
8. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009; 119(7):931-939.
9. Nanjee MN, Cooke CJ, Olszewski WL, Miller NE. Lipid and apolipoprotein concentrations in prenodal leg lymph of fasted humans. Associations with plasma concentrations in normal subjects, lipoprotein lipase deficiency, and LCAT deficiency. J Lipid Res. 2000;41(8):1317-1327.
10. Krogstad AL, Jansson PA, Gisslen P, Lonnroth P. Microdialysis methodology for the measurement of dermal interstitial fluid in humans. Br J Dermatol. 1996;134(6):1005-1012.
11. Schmelz M, Luz O, Averbeck B, Bickel A. Plasma extravasation and neuropeptide release in human skin as measured by intradermal microdialysis. Neurosci Lett. 1997;230(2):117-120.
12. Rutili G, Arfors KE. Collections of interstitial fluid: a comparison between wick and micropuncture techniques. Microvasc Res. 1978;15(1):107-109.
13. Duverger N, Ghalim N, Ailhaud G, Steinmetz A, Fruchart JC, Castro G. Characterization of apoAIV-containing lipoprotein particles isolated from human plasma and interstitial fluid. Arterioscler Thromb. 1993;13(1):126-132.
14. Kiistala U. Suction blister device for separation of viable epidermis from dermis. J Invest Dermatol. 1968; 50(2):129-137.
15. Sloop CH, Dory L, Roheim PS. Interstitial fluid lipoproteins. J Lipid Res. 1987;28(3):225-237.
16. Baluk P, et al. Functionally specialized junctions between endothelial cells of lymphatic vessels. J Exp Med. 2007;204(10):2349-2362.
17. Dixon JB, Raghunathan S, Swartz MA. A tissueengineered model of the intestinal lacteal for evaluating lipid transport by lymphatics. Biotechnol Bioeng. 2009;103(6):1224-1235.
18. Reichl D, Pflug JJ. The concentration of 935 apolipoprotein A-I in human peripheral lymph. Biochim Biophys Acta. 1982;710(3):456-463.
19. Reichl D, Rudra DN, Pflug J. The concentration of apolipoprotein A-II in human peripheral lymph. Biochim Biophys Acta. 1989;1006(2):246-249.
20. Reichl D, Myant NB, Pflug JJ. Concentration of lipoproteins containing apolipoprotein B in human peripheral lymph. Biochim Biophys Acta. 1977; 489(1):98-105.
21. Hong JL, Pflug J, Reichl D. Comparison of apoprotein B of low density lipoproteins of human interstitial fluid and plasma. Biochem J. 1984;222(1):49-55.
22. Reichl D, Postiglione A, Myant NB, Pflug JJ, Press M. Observations on the passage of apoproteins from plasma lipoproteins into peripheral lymph in two men. Clin Sci Mol Med. 1975;49(5):419-426.
23. Reichl D, Simons LA, Myant NB, Pflug JJ, Mills GL. The lipids and lipoproteins of human peripheral lymph, with observations on the transport of cholesterol from plasma and tissues into lymph. Clin Sci Mol Med. 1973;45(3):313-329.
24. Rudra DN, Myant NB, Pflug JJ, Reichl D. The distribution of cholesterol and apoprotein A-I between the lipoproteins in plasma and peripheral lymph from normal human subjects. Atherosclerosis. 1984;53(3):297-308.
25. Reichl D, Miller NE. The anatomy and physiology of reverse cholesterol transport. Clin Sci (Lond). 1986;70(3):221-231.
26. Reichl D, Hathaway CB, Sterchi JM, Miller NE. Lipoproteins of human peripheral lymph. Apolipoprotein AI-containing lipoprotein with alpha-2 electrophoretic mobility. Eur J Clin Invest. 1991;21(6):638-643.
27. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-β-migrating highdensity lipoprotein. Biochemistry. 1988;27(1):25-29.
28. Reichl D, Miller NE, Sterchi JM. Gemfibrozil increases apolipoprotein A-I and cholesterol concentrations in human peripheral lymph. Eur J Clin Invest. 1993;23(4):254-258.
29. Nanjee MN, Cooke CJ, Wong JS, Hamilton RL, Olszewski WL, Miller NE. Composition and ultrastructure of size subclasses of normal human peripheral lymph lipoproteins: quantification of cholesterol uptake by HDL in tissue fluids. J Lipid Res. 2001;42(4):639-648.
30. Engeset A, Hager B, Nesheim A, Kolbenstvedt A. Studies on human peripheral lymph. I. Sampling method. Lymphology. 1973;6(1):1-5.
31. Nanjee MN, et al. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res. 2001;42(10):1586-1593.
32. Nanjee MN, Cooke CJ, Olszewski WL, Miller NE. Concentrations of electrophoretic and size subclasses of apolipoprotein A-I-containing particles in human peripheral lymph. Arterioscler Thromb Vasc Biol. 2000;20(9):2148-2155.
33. Hovorka R, Nanjee MN, Cooke CJ, Miller IP, Olszewski WL, Miller NE. Mass kinetics of apolipoprotein A-I in interstitial fluid after administration of intravenous apolipoprotein A-I/lecithin discs in humans. J Lipid Res. 2006;47(5):975-981.
34. Miller NE, Nestel PJ, Clifton-Bligh P. Relationships between plasma lipoprotein cholesterol concentrations and the pool size and metabolism of cholesterol in man. Atherosclerosis. 1976;23(3):535-547.
35. Martel C, et al. Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice. J Clin Invest. 2013;123(4):1571-1579.
36. Lim HY, et al. Lymphatic vessels are essential for the removal of cholesterol from peripheral tissues by SR-BI-mediated transport of HDL. Cell Metab. 2013;17(5):671-684.
37. Nanjee MN, Doran JE, Lerch PG, Miller NE. Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol. 1999; 19(4):979-989.
38. Kujiraoka T, et al. Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on LCAT, PLTP, and CETP in plasma and peripheral lymph in humans. Arterioscler Thromb Vasc Biol. 2003; 23(9):1653-1659.
39. Rohrer L, Cavelier C, Fuchs S, Schluter MA, Volker W, von Eckardstein A. Binding, internalization and transport of apolipoprotein A-I by vascular endothelial cells. Biochim Biophys Acta. 2006;1761(2):186-194.
40. Cavelier C, Ohnsorg PM, Rohrer L, von Eckardstein A. The beta-chain of cell surface F(0)F(1) ATPase modulates apoA-I and HDL transcytosis through aortic endothelial cells. Arterioscler Thromb Vasc Biol. 2012;32(1):131-139.
41. Nordestgaard BG, Stender S, Kjeldsen K. Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall. Arteriosclerosis. 1988;8(4):421-428.
42. Miller NE, et al. Secretion of adipokines by human adipose tissue in vivo: partitioning between capillary and lymphatic transport. Am J Physiol Endocrinol Metab. 2011;301(4):E659-E667.
43. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophysi Acta. 1981;665(3):408-419.
44. Cheung MC, Albers JJ. Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem. 1984;259(19):12201-12209.
45. Alaupovic P, Furman RH, Falor WH, Sullivan ML, Walraven SL, Olson AC. Isolation and characterization of human chyle chylomicrons and lipoproteins. Ann N Y Acad Sci. 1968;149(2):791-807.
46. Kostner G, Holasek A. Characterization and quantitation of the apolipoproteins from human chyle chylomicrons. Biochemistry. 1972; 11(7):1217-1223.
47. Schmid-Schonbein GW. Microlymphatics and lymph flow. Physiol Rev. 1990;70(4):987-1028.
48. Muthuchamy M, Zawieja D. Molecular regulation of lymphatic contractility. Ann N Y Acad Sci. 2008;1131:89-99.
49. Dixon JB. Mechanisms of chylomicron uptake into lacteals. Ann N Y Acad Sci. 2010; 1207(suppl 1):E52-E57.
50. Deitch EA. Gut lymph and lymphatics: a source of factors leading to organ injury and dysfunction. Ann N Y Acad Sci. 2010;1207(suppl 1):E103-E111.
51. Lichtenstein L, et al. Angptl4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages. Cell Metab. 2010;12(6):580-592.
52. Navab M, et al. High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature. Arterioscler Thromb Vasc Biol. 2012;32(11):2553-2560.
53. Bura KS, et al. Intestinal SR-BI does not impact cholesterol absorption or transintestinal cholesterol efflux in mice. J Lipid Res. 2013;54(6):1567- 1577.
54. Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci U S A. 1997;94(23):12610-12615.
55. Varban ML, et al. Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol. Proc Natl Acad Sci U S A. 1998;95(8):4619-4624.
56. Nofer JR, van Eck M. HDL scavenger receptor class B type I and platelet function. Curr Opin Lipidol. 2011;22(4):277-282.
57. Bertozzi CC, Hess PR, Kahn ML. Platelets: covert regulators of lymphatic development. Arterioscler Thromb Vasc Biol. 2010;30(12):2368-2371.
58. Uhrin P, et al. Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. Blood. 2010;115(19):3997-4005.
59. Carramolino L, Fuentes J, Garcia-Andres C, Azcoitia V, Riethmacher D, Torres M. Platelets play an essential role in separating the blood and lymphatic vasculatures during embryonic angiogenesis. Circ Res. 2010;106(7):1197-1201.
60. Huby T, et al. Knockdown expression and hepatic deficiency reveal an atheroprotective role for SR-BI in liver and peripheral tissues. J Clin Invest. 2006;116(10):2767-2776.
61. Ohnsorg PM, et al. Carboxyl terminus of apolipoprotein A-I (ApoA-I) is necessary for the transport of lipid-free ApoA-I but not prelipidated ApoA-I particles through aortic endothelial cells. J Bio Chem. 2011;286(10):7744-7754.
62. Van Dyck F, et al. Loss of the PlagL2 transcription factor affects lacteal uptake of chylomicrons. Cell Metab. 2007;6(5):406-413.
63. Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol. 2002;1(1):1.
64. Lee JS. Tissue fluid pressure, lymph pressure, and fluid transport in rat intestinal villi. Microvasc Res. 1986;31(2):170-183.
65. Chang SY, et al. Circulatory antigen processing by mucosal dendritic cells controls CD8(+) T cell activation. Immunity. 2013;38(1):153-165.
66. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231-248.
67. Kohan AB, Vandersall AE, Yang Q, Xu M, Jandacek RJ, Tso P. The transport of DDT from chylomicrons to adipocytes does not mimic triacylglycerol transport. Biochim Biophys Acta. 2013;1831(2):300-305.
68. Kholova I, et al. Lymphatic vasculature is increased in heart valves, ischaemic and inflamed hearts and in cholesterol-rich and calcified atherosclerotic lesions. Eur J Clin Invest. 2010;41(5):487-497.
69. Martel C, Randolph GJ. Atherosclerosis and transit of HDL through the lymphatic vasculature. Curr Atheroscler Rep. 2013;15(9):354.
70. Nordestgaard BG, Hjelms E, Stender S, Kjeldsen K. Different efflux pathways for high and low density lipoproteins from porcine aortic intima. Arteriosclerosis. 1990;10(3):477-485.
71. Hjelms E, Nordestgaard BG, Stender S, Kjeldsen K. A surgical model to study in vivo efflux of cholesterol from porcine aorta. Evidence for cholesteryl ester transfer through the aortic wall. Atherosclerosis. 1989;77(2-3):239-249.
72. DiDonato JA, et al. Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma. Circulation. 2013;128(15):1644-1655.
73. Zabalawi M, et al. Inflammation and skin cholesterol in LDLr-/-, apoA-I-/-mice: link between cholesterol homeostasis and self-tolerance? J Lipid Res. 2007;48(1):52-65.
74. Lim HY, et al. Hypercholesterolemic mice exhibit lymphatic vessel dysfunction and degeneration. Am J Pathol. 2009;175(3):1328-1337.
75. Easton R, Gille A, D'Andrea D, Davis R, Wright SD, Shear C. A multiple ascending dose study of CSL112, an infused formulation of ApoA-I [published online ahead of print October 3, 2013]. J Clin Pharmacol. doi:10.1002/jcph.194.
76. Fidge N, Nestel P, Ishikawa T, Reardon M, Billington T. Turnover of apoproteins A-I and A-II of high density lipoprotein and the relationship to other lipoproteins in normal and hyperlipidemic individuals. Metabolism. 1980;29(7):643-653.